These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33735915)

  • 1. Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.
    Nair N; De Wolf D; Nguyen PA; Pham QH; Samara-Kuko E; Landau J; Blouse GE; Chuah MK; VandenDriessche T
    Blood; 2021 May; 137(21):2902-2906. PubMed ID: 33735915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo.
    Kao CY; Yang SJ; Tao MH; Jeng YM; Yu IS; Lin SW
    Thromb Haemost; 2013 Aug; 110(2):244-56. PubMed ID: 23676890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.
    Finn JD; Nichols TC; Svoronos N; Merricks EP; Bellenger DA; Zhou S; Simioni P; High KA; Arruda VR
    Blood; 2012 Nov; 120(23):4521-3. PubMed ID: 22919027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
    Samelson-Jones BJ; Finn JD; George LA; Camire RM; Arruda VR
    JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31219805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
    Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
    Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemophilia Gene Therapy: Ready for Prime Time?
    VandenDriessche T; Chuah MK
    Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
    Zhang R; Wang Q; Zhang L; Chen S
    Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What´s new in Gene Therapy of Hemophilia.
    Rodriguez-Merchan EC
    Curr Gene Ther; 2018; 18(2):107-114. PubMed ID: 29446741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
    George LA; Sullivan SK; Giermasz A; Rasko JEJ; Samelson-Jones BJ; Ducore J; Cuker A; Sullivan LM; Majumdar S; Teitel J; McGuinn CE; Ragni MV; Luk AY; Hui D; Wright JF; Chen Y; Liu Y; Wachtel K; Winters A; Tiefenbacher S; Arruda VR; van der Loo JCM; Zelenaia O; Takefman D; Carr ME; Couto LB; Anguela XM; High KA
    N Engl J Med; 2017 Dec; 377(23):2215-2227. PubMed ID: 29211678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.
    Cantore A; Nair N; Della Valle P; Di Matteo M; Màtrai J; Sanvito F; Brombin C; Di Serio C; D'Angelo A; Chuah M; Naldini L; Vandendriessche T
    Blood; 2012 Nov; 120(23):4517-20. PubMed ID: 23043073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction.
    Coyle CW; Knight KA; Brown HC; George SN; Denning G; Branella GM; Childers KC; Spiegel PC; Spencer HT; Doering CB
    J Thromb Haemost; 2024 Mar; 22(3):633-644. PubMed ID: 38016519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy.
    Nair N; Rincon MY; Evens H; Sarcar S; Dastidar S; Samara-Kuko E; Ghandeharian O; Man Viecelli H; Thöny B; De Bleser P; VandenDriessche T; Chuah MK
    Blood; 2014 May; 123(20):3195-9. PubMed ID: 24637359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies.
    Foley JH; Shehu E; Riddell A; Gray E; Goodale A; Yu IM; Verhoef D; Little J; Shattock D; Kitchen S; Chowdary P; Corbau R; Nathwani AC
    Blood Adv; 2023 Feb; 7(3):458-467. PubMed ID: 35839077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.
    Manno CS; Chew AJ; Hutchison S; Larson PJ; Herzog RW; Arruda VR; Tai SJ; Ragni MV; Thompson A; Ozelo M; Couto LB; Leonard DG; Johnson FA; McClelland A; Scallan C; Skarsgard E; Flake AW; Kay MA; High KA; Glader B
    Blood; 2003 Apr; 101(8):2963-72. PubMed ID: 12515715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice.
    Le Quellec S; Dane AP; Barbon E; Bordet JC; Mingozzi F; Dargaud Y; Marais T; Biferi MG; Négrier C; Nathawani AC; Enjolras N
    Thromb Haemost; 2019 Dec; 119(12):1956-1967. PubMed ID: 31659733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy.
    Di Matteo M; Samara-Kuko E; Ward NJ; Waddington SN; McVey JH; Chuah MK; VandenDriessche T
    Mol Ther; 2014 Sep; 22(9):1614-24. PubMed ID: 25034357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
    Cohn EF; Zhuo J; Kelly ME; Chao HJ
    J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.
    Konkle BA; Walsh CE; Escobar MA; Josephson NC; Young G; von Drygalski A; McPhee SWJ; Samulski RJ; Bilic I; de la Rosa M; Reipert BM; Rottensteiner H; Scheiflinger F; Chapin JC; Ewenstein B; Monahan PE
    Blood; 2021 Feb; 137(6):763-774. PubMed ID: 33067633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.